[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Skane University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":370},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,44,67,99,140,162,185,200,231,256,277,299,323,347],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100429399","central-vein-stenosis-due-to-dialysis-catheter-insertion-in-subclavian-compared-to-jugular-vein-100429399",false,"NCT04871568","Central Vein Stenosis Due to Dialysis Catheter Insertion in Subclavian Compared to Jugular Vein","Central Venous Stenosis Incidence After Right-sided Subclavian and Internal Jugular Vein Catheterization With a Silicone Temporary Hemodialysis Catheter","CITES","Inclusion Criteria:\n\n* Adults (18 years of age or older).\n* In need of a tCDC with an expected treatment time of at least 7 days.\n* Informed consent.\n\nExclusion Criteria:\n\n* Intravenous pacemaker or a PICC-line via right-sided central veins in situ.\n* Known right-sided CVS.\n* AV fistula on the right upper extremity.\n* History of central venous vascular interventions including stents, dilatations and more (but not previous central venous catheterization).\n* Central venous catheter in the right internal jugular vein or in the right subclavian vein in situ.\n* Either the right jugular vein or the right subclavian vein unavailable for catheterization due to, e.g., local skin infection, thrombosis or inability to visualize the vein with ultrasound.\n* Known allergy to iodinated contrast agents.\n* BMI \\>35 kg\u002Fm2.\n* No study physician available for the catheterization.","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","Central vein stenosis (CVS) is a well-known complication of central venous catheterization, especially after insertion of temporary hemodialysis catheters (tHDC). Incidence and prevalence differ between studies, and exact figures are hard to tell since proper venographies seldom are performed unless the patient is symptomatic.\n\nMost tHDC are placed in the jugular or femoral veins as catheters in the subclavian veins have been shown to result in CVS to a greater degree. However, some studies are equivocal and there are several advantages with the subclavian vein such as a lower risk for infectious and thrombotic complications, longer durability (thereby avoiding placement of a new catheter with repeated tissue trauma), increased comfort during insertion and use, less effect on blood flow if the patient moves the head, easier to mobilize.\n\nThe studies on CVS incidence originate from the 1990s when ultrasound-guided insertions were unheard of and polyurethane catheters were prevalent. The investigators believe that there is less tissue trauma when using ultrasound guidance in real-time. Furthermore, CVS is less common when silicone catheters are used instead of polyurethane catheters.\n\nTo avoid unnecessary vascular trauma and patient suffering, any pre-existing CVS should ideally be detected before cannulation attempts. A CT scan of the chest with IV contrast is preferred, but this exposes the patient to ionized radiation, is time-consuming and (although debated) may cause contrast-induced nephropathy. A brief ultrasound examination to verify central venous patency would be useful provided it is shown to have an adequate sensitivity for stenosis detection.",[27,28],"Subclavian Vein Stenosis","Jugular Vein Occlusion",[30],"Central Venous Stenosis","RECRUITING","2026-04-27",{"date":34,"type":35},"2026-04-29","ACTUAL",{"date":37,"type":35},"2021-11-15",{"date":39,"type":21},"2026-12-31",{"name":41,"class":42},"Skane University Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":43},"100397102","acute-colon-resection-versus-bridge-to-colon-surgery-with-stent-or-stoma-100397102","NCT04450758","Acute Colon Resection Versus Bridge to Colon Surgery With Stent or Stoma","Acute Colon Resection Versus Bridge to Colon Surgery With Stent or Stoma: a Prospective Cohort Study","ACBC","Inclusion Criteria:\n\n* Age \\>18 years\n* Symptomatic large bowel obstruction requiring acute intervention\n* CT-verified colon obstruction due to colon cancer independent of presence of metastases\n* Informed consent\n\nExclusion Criteria:\n\n* Colonic perforation or bleeding\n* Colonic obstruction of other origin than colon cancer\n* Palliative situation","100 Years",{"count":54,"type":21},1000,"OBSERVATIONAL","P) patients with acute obstructive colon cancer I) resection or bridge to surgery with stent or stoma C) emergency procedure O ) morbidity and mortality within 30 days, 90 day mortality and 3 \\& 5 years overall survival",[58],"Colon Cancer","2026-04-22",{"date":61,"type":35},"2026-04-23",{"date":63,"type":35},"2020-09-01",{"date":65,"type":21},"2031-12-31",{"name":41,"class":42},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":78,"conditions":79,"keywords":87,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},"100634736","phase-3-selenium-intervention-registry-randomized-trial-in-heart-failure-100634736","NCT07543562","Selenium Intervention Registry Randomized Trial in Heart Failure","SIRI-HF","Inclusion Criteria:\n\nTo be considered for inclusion in this study, patients must meet all of the following eligibility requirements:\n\n* 18 years of age\n* primary discharge diagnosis of HF coded as ICD-10: I50, as recorded in The SwedeHF registry\n* be able to provide documented informed consent by signing and dating the designated consent form.\n\nExclusion Criteria:\n\n* Not suitable in the opinion of the Investigator (for example due to severe or terminal comorbidity with poor prognosis, or characteristics, pregnancy etc.) that may interfere with adherence to trial protocol",{"count":75,"type":21},4326,[77],"PHASE3","Heart failure is a serious condition in which the heart is unable to pump blood effectively, and it remains a leading cause of hospitalization and death worldwide despite advances in treatment.\n\nSelenium is an essential micronutrient that plays an important role in cellular energy production, antioxidant defense, and overall cardiovascular function. Low selenium levels are common among patients with heart failure in Northern Europe, and observational studies have shown that selenium deficiency is associated with an increased risk of hospitalization and death. In cases of severe deficiency, such as in Keshan disease, heart dysfunction can be reversed with selenium supplementation, suggesting a potential causal relationship.\n\nHowever, it is not yet known whether selenium supplementation can improve clinical outcomes in patients with heart failure when added to standard medical therapy.\n\nThe SIRI-HF trial is a randomized, placebo-controlled study designed to evaluate whether daily supplementation with 200 micrograms of selenium, in addition to guideline-directed medical therapy, improves outcomes in patients with heart failure.\n\nThe primary endpoint is a composite of recurrent heart failure hospitalizations and cardiovascular death. Secondary endpoints include all-cause mortality, changes in symptoms and functional status, and safety outcomes.\n\nThis study will include patients from Sweden and Norway and aims to determine whether correcting selenium deficiency can improve prognosis in heart failure.",[80,81,82,83,84,85,86],"Heart Failure","Heart Failure and Reduced Ejection Fraction","Heart Failure and Mildly Reduced Ejection Fraction","Heart Failure and Preserved Ejection Fraction","Selenium Supplementation","Selenium","Cognitive Functioning",[88,89,90,72],"heart failure","selenium","RRCT","2026-04-15",{"date":59,"type":35},{"date":94,"type":35},"2026-04-01",{"date":96,"type":21},"2031-03",{"name":41,"class":42},11,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":106,"sex":17,"minAge":107,"maxAge":52,"enrollmentInfo":108,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":110,"conditions":111,"keywords":117,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":43},"100633985","the-swedish-biofinder-sleep-study-100633985","NCT07533799","The Swedish BioFINDER Sleep Study","BioFINDER-Sleep: Idiopathic REM-sleep Behavior Disorder & Early Parkinson's Disease","Inclusion Criteria:\n\nIdiopathic RBD:\n\n* Polysomnography verified RBD according to AASM criteria.\n* Does not fulfill diagnostic criteria for idiopathic Parkinson´s disease.\n* Age range 50-100. Women who are \\\u003C55 years of age will be required to take a pregnancy test before participation in the PET and scintigraphy part of the study if not post-menopausal.\n* Ability to give informed consent.\n* Speaks and understands Swedish to the extent that an interpreter is not necessary for the patient to fully understand the study information and cognitive tests.\n\nEarly Parkinson´s disease:\n\n* Fulfills the diagnostic criteria for idiopathic Parkinson´s disease.\n* The PD patients will be de novo (yet without any PD treatment) or with treatment for a maximum of 3 years.\n* Age range 50-100. Women who are \\\u003C55 years of age will be required to take a pregnancy test before participation in the PET and scintigraphy part of the study if not post-menopausal.\n* Ability to give informed consent.\n* Speaks Swedish fluently as stated above. Healthy Controls\n* Age range 50-100. Women who are \\\u003C55 years of age will be required to take a pregnancy test before participation in the PET and scintigraphy part of the study if not post-menopausal.\n* No diagnosis of PD or another significant neurological disorder.\n* No diagnosis of RBD.\n* Ability to give informed consent.\n* Speaks Swedish fluently as stated above.\n\nExclusion Criteria:\n\nFor all groups:\n\n* Past history of severe or repeated concussive head injury or stroke or any significant systemic disease or unstable medical condition.\n* History of severe and unstable depression, schizophrenia, schizoaffective disorder or bipolar disorder.\n* Significant white matter microvascular disease.\n* Contraindication to MRI and PET.\n\nExclusion criteria specific for early Parkinson´s disease:\n\n* Normal dopamine transporter (\\[18F\\]FE-PE2I) scan.",true,"50 Years",{"count":109,"type":21},650,"BioFINDER-Sleep study was established in 2021 and will include patients with early Parkinson´s disease (PD) and persons with iRBD to provide essential insights into the underlying mechanisms of the progressive neurodegenerative processes in central and peripheral nervous systems. Briefly polysomnography will be used to establish the presence of RBD in both the early PD cohort and in the iRBD cohort. Then, state of the art multimodal imaging techniques will be used, including, magnetic resonance imaging (MRI), positron emission tomography (PET) of the dopamine transporters (DAT-PET) to quantify dopamine terminal loss, and \\[123I\\] MIBG scintigraphy of the heart will be performed to quantify the loss noradrenaline terminals to the heart. In addition to this, synuclein seed amplification assays (SSAs) will be applied to cerebrospinal fluid (CSF) and skin samples to establish synuclein pathology status. Further, CSF and blood biomarkers will be developed that can be used to as prognostic markers. These investigations will be done in parallel to clinical assessments of motor and non-motor symptoms as well as assessment of cognitive function in a longitudinal setting.",[112,113,114,115,116],"Parkinson´s Disease","REM Sleep Behavior Disorder (iRBD)","Lewy Body Disease","Synucleinopathy","Synucleinopathies",[118,119,120,121,122,123,124,125,126,127,128,129,130,131],"Early diagnosis","CSF","Plasma","PET","MRI","DAT PET","Smell test","synuclein seed amplification assays","MIBG","Polysomnography","α-synuclein","Motoric test","cognitive test","UPDRS","2026-04-09",{"date":134,"type":35},"2026-04-16",{"date":136,"type":35},"2021-10-01",{"date":138,"type":21},"2033-06",{"name":41,"class":42},{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":107,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":149,"conditions":150,"keywords":154,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":161,"locationsCount":43},"100525423","the-swedish-biofinder---preclinical-ad-study-100525423","NCT06121544","The Swedish BioFINDER - Preclinical AD Study","Inclusion Criteria:\n\n1. Age 50-80\n2. Individuals aged 50-60 require at least one of the following risk factors for AD:\n\n   1. Known apolipoprotein E (APOE) -ε4 carrier\n   2. Known 1st degree family history of dementia or severe memory loss with onset prior to 75.\n   3. Known amyloid brain pathology by either CSF or PET scan.\n3. Mini-Mental State Examination (MMSE) ≥26 (aged \\>65); MMSE ≥27 (aged 50-65).\n4. Score of 12 or above on the Montreal Cognitive Assessment (MoCA) telephone version.\n5. Speaks and understands Swedish to the extent that an interpreter is not necessary to fully understand the study information and cognitive tests.\n\n6a. Preclinical Alzheimer's disease subgroup (n=450): Amyloid pathology according to cerebrospinal fluid Alzheimer's disease and amyloid PET scans.\n\n6b. Non-Preclinical Alzheimer's disease subgroup (n=150): No sign of preclinical Alzheimer's disease using cerebrospinal fluid Alzheimer's disease biomarkers or Aβ-PET scans.\n\nExclusion Criteria:\n\n1. Fulfils the criteria for minor or major neurocognitive disorder according to The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).\n2. History of significant brain injury or other known neurologic disease or insult, resulting in lasting cognitive sequelae that would confound the assessment and staging of potential neurodegenerative disease.\n3. Major depression, bipolar disorder, or recurrent psychotic disorders within the past year.\n4. History of alcohol and\u002For substance abuse or dependence within the past year.\n5. Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n6. Refusing or unable to complete baseline cognitive and biomarker assessments (i.e., cognitive testing, blood draw, MRI and PET).","80 Years",{"count":148,"type":21},800,"This research study aims to examine biomarkers of Alzheimer's disease (AD) as early as possible which could potentially be a screening tool for the general population. This observational study will take place at the Skåne University Hospital in Sweden. The study will enroll up to 600 cognitively healthy subjects aged 50 to 80 years with 3\u002F4 having preclinical Alzheimer's disease. Recruitment and enrollment will be ongoing for 2-3 years, and subject participation will be lasting approximately 4 years. Disclosure of AD risk assessments will be an optional procedure.",[151,152,153],"Alzheimer Disease","Mild Cognitive Impairment","Mild Dementia",[155],"Preclinical Alzheimer, early diagnosis, biomarkers, plasma, CSF, PET",{"date":157,"type":35},"2026-04-06",{"date":159,"type":35},"2022-04-01",{"date":39,"type":21},{"name":41,"class":42},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":169,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":172,"conditions":173,"keywords":177,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":179,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":43},"100525332","the-swedish-biofinder---primary-care-study-100525332","NCT06120361","The Swedish BioFINDER - Primary Care Study","ADetect","Inclusion Criteria:\n\n1. The patient seeks medical help because of cognitive symptoms experienced by the patient and\u002For informant OR The general practitioner suspects a progressive neurodegenerative disorder including, but not limited to, Alzheimer's disease, Lewy body disease, frontotemporal lobar degeneration or subcortical vascular cognitive impairment.\n2. The main symptom is usually memory complaints, but could also be executive, visuo-spatial, language, or attention complaints.\n3. Age ≥40 years\n4. Subjective cognitive decline, mild cognitive impairment or mild dementia\n\nExclusion Criteria:\n\n1. Already diagnosed dementia\n2. Significant unstable systemic illness or organ failure that makes it difficult to participate.\n3. Current significant alcohol or substance misuse.\n4. Refusing investigation at the Memory clinic\n5. Cognitive impairment with acute onset due to stroke\n6. The cognitive impairment can with certainty be explained by another condition or disease such as significant anemia, infection, severe sleep deprivation, psychotic disorder, moderate-severe depression, alcohol abuse etc.","40 Years",{"count":171,"type":21},1200,"The overall aim of the study is to improve the diagnostic accuracy of AD and cognitive impairment in primary care settings to ensure better care and treatment as well as facilitate correct referrals to specialized memory clinics. The investigators will strive to recruit diverse and representative populations of patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI) and mild dementia. The specific aims of the study are to:\n\n1. Improve the detection of mild cognitive impairment (MCI) and dementia in primary care.\n2. Develop and evaluate cognitive tests, blood-based biomarkers and brain imaging methods that are suitable for accurate and early diagnosis of Alzheimer's disease (AD) in primary care.\n3. To prospectively validate plasma AD biomarkers for diagnosis of patients with cognitive symptoms who are evaluated in primary care.\n4. Determine whether blood AD biomarkers improve patient management in primary care.",[153,152,174,151,114,175,176],"SCD","Frontotemporal Degeneration","Vascular Dementia",[178],"Primary care, early diagnosis, blood, biomarkers, cognitive testing",{"date":157,"type":35},{"date":181,"type":35},"2020-01-01",{"date":183,"type":21},"2028-12-31",{"name":41,"class":42},{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":195,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":199,"locationsCount":43},"100525490","the-swedish-biofinder---memory-clinic-study-100525490","NCT06122415","The Swedish BioFINDER - Memory Clinic Study","Validate","Inclusion Criteria:\n\n1. Under investigation for cognitive symptoms at the Memory clinic.\n2. Cerebrospinal fluid and blood sampling is planned to be done as part of clinical practice even if the patient is not taking part of this study.\n\nExclusion Criteria:\n\n1. Not undergoing CSF or blood sampling as part of clinical practice.\n2. Not undergoing cognitive testing as part of clinical practice.",{"count":171,"type":21},"The diagnosis of diseases causing memory difficulties or dementia is often challenging. Without the use of advanced methods such as cerebrospinal fluid tests, approximately 25-30% do not receive a correct diagnosis today. However, the investigators have recently developed new blood biomarkers with high diagnostic accuracy, and the investigators now want to investigate whether they can eventually replace cerebrospinal fluid tests. This is because blood tests are much more cost-effective and significantly easier for patients compared to cerebrospinal fluid tests.\n\nIn this study, 1200 patients undergoing clinical evaluations at the Memory Clinic, Skåne University Hospital in Malmö, are included for blood and cerebrospinal fluid sample collection. The blood samples are sent for analysis using the new blood biomarkers. Subsequently, the results are compared with those from the clinical analysis of cerebrospinal fluid to determine how well they perform in routine clinical practice as an alternative to cerebrospinal fluid tests and whether the blood test improves patient care. This comparison is carried out by the attending physician in three steps:\n\n1. Assessment without access to the results of either the blood test or cerebrospinal fluid test.\n2. Assessment with access to only the results of the blood test.\n3. Assessment with access to the results of both the blood test and cerebrospinal fluid test.\n\nAim 1) To prospectively validate plasma Alzheimer's disease (AD) biomarkers for diagnosis of patients with cognitive symptoms who are evaluated in a specialist memory clinic.\n\nAim 2) Determine whether blood AD biomarkers improve patient management in specialist memory clinic settings.",[153,152,174,151,114,175,176],{"date":157,"type":35},{"date":197,"type":35},"2022-12-01",{"date":39,"type":21},{"name":41,"class":42},{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":106,"sex":17,"minAge":207,"maxAge":52,"enrollmentInfo":208,"targetDuration":4,"studyType":22,"phases":210,"briefSummary":211,"conditions":212,"keywords":222,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":224,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":230},"100299199","the-swedish-biofinder-2-study-100299199","NCT03174938","The Swedish BioFINDER 2 Study","BioFINDER2","COHORT A: Cognitively healthy younger individuals (40-65 years of age) INCLUSION CRITERIA\n\n* Age 40-65 years\n* Absence of cognitive symptoms as assessed by a physician with special interest in cognitive disorders.\n* MMSE score 27-30 at screening visit.\n* Do not fulfill the criteria for MCI or any dementia according to DSM-V.\n* Speaks and understands Swedish to the extent that an interpreter is not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Significant neurological or psychiatric illness.\n* Refusing lumbar puncture, MRI or PET.\n\nCOHORT B: Cognitively healthy elderly individuals (66-100 years of age) INCLUSION CRITERIA\n\n* Age 66-100 years\n* Absence of cognitive symptoms as assessed by a physician with special interest in cognitive disorders.\n* MMSE score 26-30 at screening visit.\n* Do not fulfill the criteria for MCI or any dementia according to DSM-V.\n* Speaks and understands Swedish to the extent that an interpreter is not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Significant neurological or psychiatric illness.\n* Refusing lumbar puncture, MRI or PET.\n\nCOHORT C: Subjective cognitive decline and mild cognitive impairment INCLUSION CRITERIA\n\n* Age 40-100 years.\n* Referred to the memory clinics due to cognitive symptoms experienced by the patient and\u002For informant. These symptoms do not have to be memory complaints, but could also be executive, visuospatial, language, praxis, psychomotor or social cognitive complaints.\n* MMSE score of 24 - 30 points.\n* Do not fulfill the criteria for any dementia (major neurocognitive disorder) according to DSM-V.\n* The medical doctor (after clinical assessments, cognitive testing, CSF analyses and structural brain imaging) believes the cognitive complaints are caused by an incipient neurocognitive disorder of any sort. This is defined as any case fulfilling the criteria above (i.e. both SCD and MCI) with an abnormal CSF Aβ42\u002F40 ratio, which is strongly associated with brain Aβ pathology and prodromal Alzheimer's disease. Further, cases with MCI (=minor neurocognitive impairment) due to either Parkinson's disease, Lewy body disease, vascular neurocognitive disorder or frontotemporal dementia (please see Appendix below for clinical criteria and references) can also be included.\n* Speaks and understands Swedish to the extent that an interpreter is not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Refusing lumbar puncture, MRI or PET.\n\nCOHORT D: Dementia due to Alzheimer's disease INCLUSION CRITERIA\n\n* Age 40-100 years.\n* Referred to the memory clinics due to cognitive symptoms experienced by the patient and\u002For informant. These symptoms do not have to be memory complaints, but could also be executive, visuospatial, language, praxis or psychomotor complaints.\n* MMSE score of 12-26 points.\n* Fulfill the criteria for dementia (major neurocognitive disorder) due to Alzheimer's disease (DSM-V).\n* Speaks and understands Swedish to the extent that an interpreter was not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Refusing lumbar puncture, MRI or PET.\n\nCOHORT E: Other dementias INCLUSION CRITERIA\n\n* Age 40-100 years.\n* Fulfill the criteria for dementia (major neurocognitive disorder) due to FTD, PDD, DLB or subcortical VaD alternatively the criteria for PD, PSP, MSA, CBS or ALS.\n* Speaks and understands Swedish to the extent that an interpreter was not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Refusing lumbar puncture, MRI or PET.","20 Years",{"count":209,"type":21},2950,[24],"The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g. to characterize the role of beta-amyloid pathology in early diagnosis of Alzheimer's disease (AD) using amyloid-PET (18F-Flutemetamol) and Aβ analysis in cerebrospinal fluid samples. The BioFINDER 1 study has resulted in more than 40 publications during the last three years, many in high impact journals, and some the of the results have already had important implications for the diagnostic work-up patients with AD in the clinical routine practice.\n\nThe original BioFINDER 1 cohort started to include participants in 2008. Since then there has been a rapid development of biochemical and neuroimaging technologies which enable novel ways to the study biological processes involved in Alzheimer's disease in living people. There has also been a growing interest in the earliest stages of AD and other neurodegenerative diseases. With the advent of new tau-PET tracers there is now an opportunity to elucidate the role of tau pathology in the pathogenesis of AD and other tauopathies. The Swedish BioFINDER 2 study has been designed to complement the BioFINDER 1 study and to e.g. address issues regarding the role of tau pathology in different dementias and in preclinical stages of different dementia diseases. Further, the clinical assessments and MRI methods have been further optimized compared to BioFINDER 1. Detailed assessments of motor aspects and dual task performance, which is part of a sub-study named Motor-ACT: \"Motor aspects and activities in relation to cognitive decline and brain pathologies, has been added to further optimize assessment of motor function.",[213,151,214,114,215,175,216,217,218,219,220,152,221],"Dementia","Parkinson Disease","Parkinson-Dementia Syndrome","Semantic Dementia","Progressive Nonfluent Aphasia","Progressive Supranuclear Palsy","Corticobasal Degeneration","Multiple System Atrophy","ALS (Amyotrophic Lateral Sclerosis)",[223],"Early diagnosis, biomarker, PET, MRI, β-amyloid, tau, CSF, cognitive test",{"date":157,"type":35},{"date":226,"type":35},"2017-05-15",{"date":228,"type":21},"2036-12",{"name":41,"class":42},2,{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":22,"phases":240,"briefSummary":241,"conditions":242,"keywords":244,"overallStatus":248,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":255,"locationsCount":4},"100625725","internet-delivered-act-targeting-emotional-distress-and-chronic-pain-100625725","NCT07426367","Internet-Delivered ACT Targeting Emotional Distress and Chronic Pain","Inclusion Criteria:\n\nemotional distress characterized by clinically significant symptoms of anxiety or depression age between 18-65 years were fully examined medically and had received medical treatment if indicated were able to be an active part of the rehabilitation process, regain functioning in different life areas and participate in treatment interventions for approximately 5 hours every week stable dose of medication able to read and write in Swedish had access to a smart phone or computer with internet access\n\nExclusion Criteria:\n\nhad acute or severe psychiatric disorders or symptoms that warranted designation as the primary disorder (ongoing substance dependence, untreated bipolar disorder, OCD, psychotic symptoms, severe depression, PTSD) were actively abusing analgesic medications (including narcotics), alcohol or other drugs had great difficulty to harbour and handle strong emotions that could lead to emotional outbursts or self-harming behavior had health risks due to medical reasons; had social or economic difficulties or lack of social support that hindered behavior change current severe suicidal ideation that warranted immediate intervention (indicated by the MINI)","65 Years",{"count":239,"type":21},10,[24],"The primary aim of this study is to investigate the effect of Internet-delivered Acceptance and commitment therapy for emotional distress and comorbid chronic pain. A pilot study ( N=5-10) will be conducted to test the intervention and assessment procedures. The participants will go through an active internet-based ACT treatment focused on education about emotional distress and pain, as well as behavior change through exercises targeting the processes mindfulness, cognitive defusion and acceptance. The treatment is delivered on a safe internet platform. Participants have planned telephone contact with their assigned psychologist 2 times during the program and can also contact their psychologist via a message system in the platform and expect answer within 48 hours.",[243],"Chronic Pain",[245,246,247],"emotional distress","ACT","chronic pain","NOT_YET_RECRUITING","2026-02-16",{"date":251,"type":35},"2026-02-23",{"date":253,"type":21},"2027-04-01",{"date":183,"type":21},{"name":41,"class":42},{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":263,"minAge":18,"maxAge":237,"enrollmentInfo":264,"targetDuration":4,"studyType":22,"phases":265,"briefSummary":266,"conditions":267,"keywords":269,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":276,"locationsCount":43},"100527864","internet-based-act-for-endometriosis-and-chronic-pain-100527864","NCT06153303","Internet-based ACT for Endometriosis and Chronic Pain","A Pilot Study of Internet-based ACT for Endometriosis and Chronic Pain","Inclusion Criteria:\n\n* verified endometriosis\n* age between 18-65 years\n* were fully examined medically and had received medical treatment if indicated\n* were able to be an active part of the rehabilitation process, regain functioning in different life areas and participate in treatment interventions for approximately 5 hours every week\n* stable dose of medication\n* able to read and write in Swedish\n* had access to a smart phone or computer with internet access\n\nExclusion Criteria:\n\n* had acute or severe psychiatric disorders or symptoms that warranted designation as the primary disorder (ongoing substance dependence, untreated bipolar disorder, OCD, psychotic symptoms, severe depression, PTSD)\n* were actively abusing analgesic medications (including narcotics), alcohol or other drugs\n* had great difficulty to harbour and handle strong emotions that could lead to emotional outbursts or self-harming behavior\n* had health risks due to medical reasons;\n* had social or economic difficulties or lack of social support that hindered behavior change\n* current severe suicidal ideation that warranted immediate intervention (indicated by the MINI and a score of 3 to item 9 of the Patient Health Questionnaire 9-item version (PHQ9))","FEMALE",{"count":239,"type":21},[24],"The primary aim of this study is to investigate the effect of Internet-delivered Acceptance and commitment therapy for endometriosis and chronic pain. A pilot study (no randomization; N=10) will be conducted to test the intervention and assessment procedures. The participants will go through an active internet-based ACT treatment focused on education about endometriosis and chronic pain, value-based exposure for avoided situations, and behavior change through exercises targeting the processes mindfulness, cognitive defusion and acceptance. The treatment is delivered on a safe internet platform. Participants have planned telephone contact with their assigned psychologist 2 times during the program and can also contact their psychologist via a message system in the platform and expect answer within 48 hours.",[268,243],"Endometriosis",[270,247],"endometriosis",{"date":272,"type":35},"2026-02-19",{"date":274,"type":35},"2024-01-01",{"date":39,"type":21},{"name":41,"class":42},{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":237,"enrollmentInfo":284,"targetDuration":4,"studyType":22,"phases":286,"briefSummary":287,"conditions":288,"keywords":290,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":293,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":43},"100450627","iact-for-ptsd-and-chronic-pain-100450627","NCT05147948","iACT for PTSD and Chronic Pain","Internet-based Acceptance and Commitment Therapy for PTSD and Chronic Pain","Inclusion Criteria:\n\n* a CAPS of ≥25\n* subjected to single traumatic events\n* were able to understand Swedish\n* had symptoms of chronic pain that interfered significantly with everyday life\n* were fully examined medically and had received medical treatment if indicated\n* were able to be an active part of the rehabilitation process, regain functioning in different life areas and participate in treatment interventions for approximately 5 hours every week\n* stable dose of medication\n* able to read and write in Swedish\n* had access to a smart phone or computer with internet access\n\nExclusion Criteria:\n\n* repeated and extensive traumatic events\n* had other acute or severe psychiatric disorders or symptoms that warranted designation as the primary disorder (ongoing substance dependence, untreated bipolar disorder, OCD, psychotic symptoms, severe depression)\n* were actively abusing analgesic medications (including narcotics), alcohol or other drugs\n* had great difficulty to harbour and handle strong emotions that could lead to emotional outbursts or self-harming behavior\n* had health risks due to medical reasons\n* had social or economic difficulties or lack of social support that hindered behavior change\n* current severe suicidal ideation that warranted immediate intervention (indicated by the MINI and a score of 3 to item 9 of the Patient Health Questionnaire 9-item version (PHQ9))",{"count":285,"type":21},40,[24],"The primary aim of this study is to investigate the effect of Internet-delivered Acceptance and commitment therapy for PTSD and comorbid chronic pain using a randomized controlled trial with waitlist control.",[289,243],"Ptsd",[291,292,246],"PTSD","Chronic pain",{"date":272,"type":35},{"date":295,"type":35},"2021-10-18",{"date":297,"type":21},"2027-12-18",{"name":41,"class":42},{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":305,"eligibilityCriteria":306,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":22,"phases":309,"briefSummary":310,"conditions":311,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":230},"100535097","effect-of-high-flow-therapy-in-long-term-oxygen-therapy-100535097","NCT06247397","Effect of HIgh-flow Therapy in Long-term Oxygen Therapy","Effect of HIgh-flow Therapy in Long-term Oxygen Therapy (HILOT): A Multicenter, Registry-based, Randomized Clinical Trial","HILOT","Inclusion Criteria:\n\n* Age 40 years or older\n* Ongoing LTOT: prescribed for at least 15 hours per day; and since at least 28 days as registered in Swedevox\n* COPD or ILD as main underlying reason for LTOT\n* Oxygen concentrator as stationary oxygen source in the home including night-time\n* Body mass index (BMI) \\\u003C 35 kg\u002Fm2\n\nExclusion Criteria:\n\n* Current or previous treatment with home HFOT\n* Current treatment with home mechanical ventilation\n* Current treatment with home CPAP\n* Hospitalized during the last 2 weeks\n* Current smoking or contact with flames\n* Self-reported average use of the LTOT \\\u003C 15h per day (24 hours)\n* PaCO2 (breathing air at rest) \\> 8 kPa\n* Strong clinical suspicion of obstructive sleep apnea (OSA) or obesity-related hypoventilation syndrome (OHS) (as judged by the responsible staff)\n* Inability to participate in the study procedures (as judged by the staff)\n* Not eligible for continuing LTOT due to other reason (as judged by the staff)\n* Expected survival less than 3 months (as judged by the staff)",{"count":308,"type":21},310,[24],"This is a registry-based, randomized, controlled clinical trial of the effect of added high-flow oxygen therapy (using the device Lumis HFT) during one year in people with long-term oxygen therapy (LTOT) for chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD).",[312,313,314],"Chronic Obstructive Pulmonary Disease Severe","Interstitial Lung Disease","Chronic Respiratory Failure With Hypoxia","2025-05-15",{"date":317,"type":35},"2025-05-21",{"date":319,"type":35},"2024-06-10",{"date":321,"type":21},"2028-12",{"name":41,"class":42},{"id":324,"slug":325,"hasResults":11,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":329,"eligibilityCriteria":330,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":22,"phases":333,"briefSummary":334,"conditions":335,"keywords":337,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":341,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":43},"100532606","selective-defunctioning-stoma-in-low-anterior-resection-for-rectal-cancer-100532606","NCT06214988","Selective Defunctioning Stoma in Low Anterior Resection for Rectal Cancer","SELective Defunctioning Stoma Approach in Low Anterior Resection for Rectal Cancer (SELSA): a Prospective Study With a Nested Randomised Clinical Trial","SELSA","Inclusion Criteria:\n\n* Adult patients with rectal cancer planned for a low anterior resection with anastomosis by TME with any surgical approach\n\nAdditional inclusion criteria for randomised part of the study:\n\n* Patients aged less than 80 years\n* Patients with American Society of Anesthetists' (ASA) fitness grade I or II as determined by the anaesthesiologist or the surgeon\n* Patients without clear radiological signs of distant disease before rectal cancer surgery (previous metastatic surgery is no exclusion criterion)\n* Anastomotic leak risk score of 0-1\n* Willingness to be randomised\n\nExclusion Criteria:\n\n* Insufficient command of Swedish, Norwegian, Danish or English to understand questionnaires or consent\n* Emergency rectal resection (tumour resection due to large bowel obstruction, perforation, etc)\n* Pregnancy or breastfeeding Additional exclusion criteria for randomised part of the study\n* Previous pelvic irradiation (due to e.g. gynaecological or urological cancer)\n* Preoperative tumour perforation or pelvic sepsis\n* Beyond TME surgery and\u002For concurrent resection of other organ\n* Concurrent corticosteroid treatment (prednisone-equivalent dosage ≥10 mg daily)\n* Planned postoperative chemotherapy\n* Smoking not completely ceased four weeks before surgery\n* Excessive alcohol consumption with social and medical consequences (as judged by the surgeon in charge) Intraoperative exclusion criteria for randomised part of the study\n\n  -\\>2 staple firings for rectal transection\n* Intraoperative blood loss ≥250 ml for minimally invasive surgery\n* Intraoperative blood loss ≥500 ml for open or converted surgery\n* More than one intraabdominal anastomosis performed\n* Incomplete doughnuts\n* Air-leak test positive\n* Any significant intraoperative adverse event at the discretion of the operating surgeon (e.g. ureterotomy, bowel or tumour perforation, major medical event - pulmonary embolism, cardiac arrhythmia) (Gawria, 2022)\n* TME with anastomosis ultimately not done",{"count":332,"type":21},212,[24],"The goal of this observational trial with a nested randomized controlled trial is to investigate a selective approach of defunctioning stoma in low anterior resection in rectal cancer patients. The primary outcome is a hybrid so-called textbook outcome; stoma-free survival at two years without major LARS, reflecting a functionally appropriate outcome after low anterior resection for rectal cancer. Secondary outcomes include anastomotic leakage, postoperative mortality, reinterventions, stoma-related complications, quality of life measures, LARS, and permanent stoma rate up to two years after index surgery.",[336],"Rectal Cancer",[338,339,340],"anterior resection","defunctioning stoma","selective approach",{"date":317,"type":35},{"date":343,"type":35},"2024-09-01",{"date":345,"type":21},"2030-12-31",{"name":41,"class":42},{"id":348,"slug":349,"hasResults":11,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":22,"phases":356,"briefSummary":357,"conditions":358,"keywords":4,"overallStatus":248,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":4},"100482915","vacuum-assisted-wound-closure-and-permanent-on-lay-mesh-mediated-fascial-traction-in-patients-with-open-abdomen-100482915","NCT05568238","Vacuum Assisted Wound Closure and Permanent On-lay Mesh-mediated Fascial Traction in Patients With Open Abdomen","Vacuum Assisted Wound Closure and Permanent On-lay Mesh-mediated Fascial Traction (VAWCPOM) in Patients With Open Abdomen - a Prospective Multi-center Cohort Study","VAWCPOM","Inclusion Criteria:\n\n• All patients ≥18 years old treated with an open abdomen with a midline incision, regardless of indication.\n\nExclusion Criteria:\n\n* Patient declining participation\n* Existing incisional hernia or primary ventral hernia ≥3 cm\n* Existing mesh in the abdominal wall, located in the midline and irrespective of mesh size\n* Existing ostomy\u002Fparastomal hernia located in a position that prevents the VAWCPOM technique to be utilized\n* Closure of the abdomen at first dressing change, e. g. without mesh traction",{"count":20,"type":21},[24],"Open abdomen therapy is used in trauma and non-trauma patients where the abdomen is not possible to close, or the intraabdominal conditions is not suitable for closure. In 2007, a new technique that made use of negative pressure wound therapy and mesh-mediated fascial traction for closure of the open abdomen was described from the Department of Surgery in Malmö, Sweden. With this new technique, fascial closure rates were high but long-term incisional hernia formation was seen in approximately half of the patients alive after five years. To overcome the high incisional hernia incidence, a new technique utilizing a permanent on-lay mesh for traction and reinforcement of the incision at fascial closure was developed.\n\nHypothesis Lower incisional hernia rates in comparison with literature reported results of other techniques for open abdomen treatment, with similar complication rates.\n\nAims To evaluate early and late clinical outcome of the novel vacuum-assisted wound closure and permanent on-lay mesh-mediated fascial traction technique.\n\nDesign A prospective six-center cohort study in Sweden and Denmark. Study inclusion during a two-year period or longer to include at least 100 patients. Statistical analysis will be done by intention-to-treat and as sub-group per-protocol analysis.",[359,360,361],"Open Abdomen","Temporary Abdominal Closure","Incisional Hernia","2022-09-30",{"date":364,"type":35},"2022-10-05",{"date":366,"type":21},"2022-10",{"date":368,"type":21},"2027-12",{"name":41,"class":42},""]